Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026

Reuters2026/08/06 11:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Climb Bio flagged initial Phase 1 data for anti-APRIL antibody CLYM116 in healthy volunteers for presentation on Sept. 3, 2026.
Early safety results for CLYM116 were already presented in June, supporting continued development in IgA nephropathy without raising new tolerability concerns.
Dosing is expected to start in Q3 2026 in a Phase 2 IgA nephropathy study run by partner Beijing Mabworks.
Budoprutug programs remain on track, with additional study readouts expected in Q4 2026 across kidney disease, ITP, and SLE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336762), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026

You may also like

Crypto prices